Periodontal DiseasesNCT07666126
Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss
An observational study of Periodontal Diseases and Hyperuricemia, run by Recep Tayyip Erdogan University Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
Periodontitis is a multifactorial disease characterized by chronic inflammation of the gum tissue and alveolar bone destruction, and is known to be associated with various systemic diseases. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Periodontal Diseases, Hyperuricemia, Oxidative Stress
- What is being tested?
- Collection of gingival crevicular fluid (GCF) and serum samples and Measurement of periodontal clinical parameters
- How many people
- 80 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 10 Jun 2026to 1 Oct 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Recep Tayyip Erdoğan University Faculty of Dentistry
Who may be able to join
- Being between 18 and 65 years of age
- Being systemically healthy or diagnosed with hyperuricemia
- Having at least 20 natural teeth
- Being periodontally healthy or diagnosed with periodontitis
Who cannot join
- Diabetes, cardiovascular disease, osteoporosis, chronic kidney disease, metabolic syndrome, and obesity are systemic diseases that may affect purine metabolism.
- Smoking
- Pregnancy or lactation
- Having received periodontal treatment within the last 3-6 months
- Use of antibiotics, anti-inflammatory drugs, or uric acid-lowering drugs
- Presence of systemic diseases that may affect purine metabolism
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
Recep Tayyip Erdoğan University
Rize, 53020
Hatice Yemenoglu, +904642220000, htcymnglu@hotmail.com
About this study
Official title: Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss and Oxidative Stress
Periodontitis is a multifactorial disease characterized by chronic inflammation of the gum tissue and alveolar bone destruction, and is known to be associated with various systemic diseases. Hyperuricemia, on the other hand, is a metabolic condition characterized by increased serum uric acid levels and can affect inflammation, oxidative stress, and bone metabolism. In recent years, the relationship between hyperuricemia and periodontal diseases has been increasingly investigated, but the biological mechanisms of this relationship have not yet been fully elucidated. Therefore, this study aimed to determine whether there is a relationship between hyperuricemia and periodontitis and to reveal the possible pathophysiological mechanisms of this relationship, which are shaped by inflammation, oxidative stress, and bone metabolism.
A total of 80 individuals aged 18-65 years will be included in this clinical observational study. The periodontal status of the participants will be assessed using clinical periodontal parameters such as probing pocket depth, clinical attachment loss, plaque index, gingival index, and bleeding on probing. Participants will be divided into four groups according to their periodontal status and the presence of hyperuricemia: individuals with periodontitis and hyperuricemia, individuals with periodontally healthy and hyperuricemia, individuals with periodontitis but without hyperuricemia, and individuals with periodontally healthy and without hyperuricemia. Gingival crevicular fluid and serum samples will be taken from the participants. In these samples, receptor-mediated nuclear factor kappa B ligand, osteoprotegerin, total antioxidant status, total oxidant status, oxidative stress index, interleukin-1 beta, interleukin-10, interleukin-18, and nucleotide-binding oligomerization domain-like receptor protein 3 levels will be analyzed. This study is considered unique because it examines the relationship between hyperuricemia and periodontitis by evaluating inflammation, oxidative stress, and bone metabolism parameters together.
- Conditions
- Periodontal Diseases, Hyperuricemia, Oxidative Stress
- Being tested
- Collection of gingival crevicular fluid (GCF) and serum samples, Measurement of periodontal clinical parameters
- Keywords
- periodontal disease, hyperuricemia, oxidative stress, alveolar bone loss, inflammation
- Medical subject headings
- Periodontal Diseases, Hyperuricemia, Alveolar Bone Loss, Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Collection of gingival crevicular fluid (GCF) and serum samplesOther
Serum and GCF samples will be collected from participants in the first session
Measurement of periodontal clinical parametersOther
Periodontal clinical parameters will be measured from participants initially
| Study group | Role | What they receive |
|---|---|---|
| Group 1: Individuals with periodontitis and hyperuricemia | Not described Receives: Other: Collection of gingival crevicular fluid (GCF) and serum samples; Other: Measurement of periodontal clinical parameters | |
| Group 2: Periodontally healthy individuals with hyperuricemia | Not described Receives: Other: Collection of gingival crevicular fluid (GCF) and serum samples; Other: Measurement of periodontal clinical parameters | |
| Group 3: Individuals with periodontitis but without hyperuricemia | Not described Receives: Other: Collection of gingival crevicular fluid (GCF) and serum samples; Other: Measurement of periodontal clinical parameters | |
| Group 4: Periodontally healthy individuals without hyperuricemia | Not described Receives: Other: Collection of gingival crevicular fluid (GCF) and serum samples; Other: Measurement of periodontal clinical parameters |
What is being measured
The primary outcome is the main question the study is designed to answer.
Periodontal pocket depth
The distance between the gingival margin and the base of the pocket will be measured in millimeters.
Measured: at baseline
clinical attachment loss
The distance between the enamel-cementum junction and the base of the pocket will be measured in millimeters.
Measured: at baseline
Secondary outcomes (3)
Level of interleukin-1 beta
Interleukin-1 beta levels will be determined from gingival crevicular fluid and serum samples using the ELISA method.
Measured: at baseline
Level of interleukin-10
Interleukin-10 levels will be determined from gingival crevicular fluid and serum samples using the ELISA method.
Measured: at baseline
Level of interleukin-18
Interleukin-18 levels will be determined from gingival crevicular fluid and serum samples using the ELISA method.
Measured: at baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jun 2026
- Study start10 Jun 2026 (estimated)
- Primary completion1 Oct 2026 (estimated)
- Study completion1 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Periodontal DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Recep Tayyip Erdogan University Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Hatice Yemenoğlu, Recep Tayyip Erdogan University Training and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07666126
- Sponsor's protocol ID
- 2025/302
- Status last verified
- Jun 2026
- First submitted
- 8 Jun 2026
- Last updated
- 26 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Effect of Hyperuricemia on Alveolar Bone Loss and Oxidative Stress
- ClinicalTrials.gov ID
- NCT07666126
- Acronym / sponsor ID
- 2025/302
- Conditions
- Periodontal Diseases, Hyperuricemia, Oxidative Stress
- Keywords
- periodontal disease, hyperuricemia, oxidative stress, alveolar bone loss, inflammation
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Recep Tayyip Erdogan University Training and Research HospitalUniversity, hospital or other
- Study start
- 10 Jun 2026 (estimated)
- Primary completion
- 1 Oct 2026 (estimated)
- Study completion
- 1 Oct 2026 (estimated)
- First posted
- 24 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Periodontitis is a multifactorial disease characterized by chronic inflammation of the gum tissue and alveolar bone destruction, and is known to be associated with various systemic diseases. Hyperuricemia, on the other hand, is a metabolic condition characterized by increased serum uric acid levels and can affect inflammation, oxidative stress, and bone metabolism. In recent years, the relationship between hyperuricemia and periodontal diseases has been increasingly investigated, but the biological mechanisms of this relationship have not yet been fully elucidated. Therefore, this study aimed to determine whether there is a relationship between hyperuricemia and periodontitis and to reveal the possible pathophysiological mechanisms of this relationship, which are shaped by inflammation, oxidative stress, and bone metabolism.
A total of 80 individuals aged 18-65 years will be included in this clinical observational study. The periodontal status of the participants will be assessed using clinical periodontal parameters such as probing pocket depth, clinical attachment loss, plaque index, gingival index, and bleeding on probing. Participants will be divided into four groups according to their periodontal status and the presence of hyperuricemia: individuals with periodontitis and hyperuricemia, individuals with periodontally healthy and hyperuricemia, individuals with periodontitis but without hyperuricemia, and individuals with periodontally healthy and without hyperuricemia. Gingival crevicular fluid and serum samples will be taken from the participants. In these samples, receptor-mediated nuclear factor kappa B ligand, osteoprotegerin, total antioxidant status, total oxidant status, oxidative stress index, interleukin-1 beta, interleukin-10, interleukin-18, and nucleotide-binding oligomerization domain-like receptor protein 3 levels will be analyzed. This study is considered unique because it examines the relationship between hyperuricemia and periodontitis by evaluating inflammation, oxidative stress, and bone metabolism parameters together.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Group 1: Individuals with periodontitis and hyperuricemia | – | Other: Collection of gingival crevicular fluid (GCF) and serum samples, Other: Measurement of periodontal clinical parameters |
| Group 2: Periodontally healthy individuals with hyperuricemia | – | Other: Collection of gingival crevicular fluid (GCF) and serum samples, Other: Measurement of periodontal clinical parameters |
| Group 3: Individuals with periodontitis but without hyperuricemia | – | Other: Collection of gingival crevicular fluid (GCF) and serum samples, Other: Measurement of periodontal clinical parameters |
| Group 4: Periodontally healthy individuals without hyperuricemia | – | Other: Collection of gingival crevicular fluid (GCF) and serum samples, Other: Measurement of periodontal clinical parameters |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Recep Tayyip Erdoğan University Faculty of Dentistry
Key inclusion criteria (4 listed)
- Being between 18 and 65 years of age
- Being systemically healthy or diagnosed with hyperuricemia
- Having at least 20 natural teeth
- Being periodontally healthy or diagnosed with periodontitis
Key exclusion criteria (6 listed)
- Diabetes, cardiovascular disease, osteoporosis, chronic kidney disease, metabolic syndrome, and obesity are systemic diseases that may affect purine metabolism.
- Smoking
- Pregnancy or lactation
- Having received periodontal treatment within the last 3-6 months
- Use of antibiotics, anti-inflammatory drugs, or uric acid-lowering drugs
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Collection of gingival crevicular fluid (GCF) and serum samplesSerum and GCF samples will be collected from participants in the first session | Other | Group 1: Individuals with periodontitis and hyperuricemia, Group 2: Periodontally healthy individuals with hyperuricemia, Group 3: Individuals with periodontitis but without hyperuricemia, Group 4: Periodontally healthy individuals without hyperuricemia |
| Measurement of periodontal clinical parametersPeriodontal clinical parameters will be measured from participants initially | Other | Group 1: Individuals with periodontitis and hyperuricemia, Group 2: Periodontally healthy individuals with hyperuricemia, Group 3: Individuals with periodontitis but without hyperuricemia, Group 4: Periodontally healthy individuals without hyperuricemia |
Primary outcome
Periodontal pocket depth
Time frame: at baseline
The distance between the gingival margin and the base of the pocket will be measured in millimeters.
clinical attachment loss
Time frame: at baseline
The distance between the enamel-cementum junction and the base of the pocket will be measured in millimeters.
3 secondary outcomes
Level of interleukin-1 beta
Time frame: at baseline
Level of interleukin-10
Time frame: at baseline
Level of interleukin-18
Time frame: at baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jun 2026.
Related trials for Periodontal Diseases
RecruitingObservational study
Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
Immunosuppression, Periodontal Disease
Not yet recruiting
Spirulina Gel in the Treatment of Periodontitis
Periodontitis, Periodontitis Stage II
Not yet recruiting
Effectiveness of Oil Pulling Using Oils in Comparison With Mouthwash for Gingivitis
Gingivitis
Active, not recruiting
NON-SURGİCAL PERİODONTAL THERAPY WİTH L-ARGİNİNE
Periodontal Disease, Periodontal Diseases
Not yet recruitingObservational study
Salivary and GCF Biomarkers in Periodontal Health, Gingivitis and Periodontitis
Periodontal Health, Gingivitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Periodontal Diseases and Hyperuricemia, run by Recep Tayyip Erdogan University Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 26 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hatice Yemenoglu (+905052977517, htcymnglu@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Periodontal pocket depth (time frame: at baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jun 2026.